

CITATION REPORT

List of articles citing

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial

DOI: 10.7326/0003-4819-130-6-199903160-00004
Annals of Internal Medicine, 1999, 130, 478-86.

Source: <https://exaly.com/paper-pdf/30652629/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1019	Building towards a consensus for the use of tumour necrosis factor blocking agents. 1999 , 58, 725-6		9
1018	Etanercept: therapeutic use in patients with rheumatoid arthritis. 1999 , 58 Suppl 1, 165-9		57
1017	PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. 1999 , 58 Suppl 1, 173-81		59
1016	New biologic agents: a critical appraisal. 1999 , 1, 470-5		1
1015	The treatment of rheumatoid arthritis: a review of recent clinical trials. 1999 , 1, 135-8		2
1014	Biologic therapies in rheumatoid arthritis. 1999 , 1, 157-63		10
1013	The genetics of rheumatoid arthritis: influences on susceptibility, severity, and treatment response. 1999 , 1, 164-71		13
1012	Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis. 1999 , 29, 172-81		46
1011	Clinical and pharmacological experience with etanercept. 1999 , 8, 1443-51		9
1010	Intercepting TNF with etanercept to treat rheumatoid arthritis. 1999 , 14, 1-5		1
1009	Case management for patients with rheumatoid arthritis. 1999 , 10, 65-72; quiz 73		
1008	Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. 1999 , 354, 1932-9		1960
1007	Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: focus on etanercept, a new biologic response modifier. 1999 , 21, 1429-42; discussion 1427-8		13
1006	Etanercept: a review of its use in rheumatoid arthritis. 1999 , 57, 945-66		132
1005	Medical management of children with juvenile rheumatoid arthritis. 1999 , 58, 831-50		21
1004	Rheumatoid Arthritis: Strategies for Pharmacotherapy. 1999 , 12, 271-281		
1003	Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. 1999 , 5, 119-33		283

1002	Advances in the medical treatment of juvenile rheumatoid arthritis. 2000 , 12, 72-5	10
1001	Sjögren syndrome. 2000 , 11, 449-54	17
1000	Musculoskeletal and systemic reactions to biological therapeutic agents. 2000 , 12, 49-52	33
999	Molecular pharmacology of immunosuppressive agents in relation to their clinical use. 2000 , 5, 268-275	9
998	New immunologic treatments for inflammatory bowel disease. 2000 , 16, 565-70	2
997	A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. 2000 , 43, 2316-27	85
996	Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. 2000 , 43, 2606-8	63
995	Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. 2000 , 43, 2648-59	119
994	Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease. 2000 , 14, 501-14	50
993	A soluble mannose receptor immunoadhesin enhances phagocytosis of <i>Pneumocystis carinii</i> by human polymorphonuclear leukocytes in vitro. 2000 , 52, 131-7	19
992	Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases. 2000 , 12, 712-8	57
991	Treatment of rheumatoid arthritis: etanercept a recent advance. 2000 , 12, 433-41; quiz 442-4	1
990	Cytokines in rheumatoid arthritis: trials and tribulations. 2000 , 6, 315-23	47
989	Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. 2000 , 30, 196-208	50
988	Anti-cytokine therapy for rheumatoid arthritis. 2000 , 51, 207-29	317
987	The role of tumor necrosis factor alpha in the pathophysiology of congestive heart failure. 2000 , 2, 189-97	26
986	Non-HIV retroviral associations with rheumatic disease. 2000 , 2, 156-62	10
985	TNF- α Receptors as Recombinant Proteins in Treatment of Rheumatoid Arthritis. 2000 , 147-153	

984 Combination Systemic Therapy in the Treatment of Psoriasis. **2000**, 6a, 1-4

983 Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. **2000**, 342, 763-9 947

982 Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha. **2000**, 59 Suppl 1, i75-80 50

981 The final pathogenetic steps in focal bone erosions in rheumatoid arthritis. **2000**, 59 Suppl 1, i72-4 12

980 Etanercept (Enbrel): update on therapeutic use. **2000**, 59 Suppl 1, i46-9 44

979 Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab. **2000**, 34, 743-60 26

978 Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. **2000**, 22, 128-39 82

977 [Value of anti-TNF-alpha molecules in inflammatory and infectious diseases]. **2000**, 21, 872-88 1

976 A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. **2000**, 343, 1586-93 1551

975 Soluble cytokine receptors: novel immunotherapeutic agents. **2000**, 9, 497-514 41

974 Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. **2000**, 356, 385-90 1187

973 Management of immune-mediated uveitis. **2000**, 13, 9-20 3

972 Management of the patient with severe refractory rheumatoid arthritis: are the newer treatment options worth considering?. **2000**, 13, 425-35 4

971 New medications for use in patients with rheumatoid arthritis. **2000**, 84, 280-4; quiz 284, 287 3

970 Geropharmacology for the rheumatologist. **2000**, 26, 433-54, v-vi 12

969 Immune function. **2000**, 47, 1197-209 9

968 Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. **2000**, 75, 1093-8 88

967 Actitudes terapéuticas. alimentaci3n. actividad f3sica. indicaciones de fisioterapia. indicaciones de tratamiento farmacol3gico. criterios de introducci3n y retirada de f3rmacos. indicaciones quir3rgicas. **2000**, 8, 1396-1401

966	Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. 2001 , 121, 1088-94	746
965	Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible. 2001 , 61, 1711-20	11
964	Are the insulin-like growth factors relevant to cancer?. 2001 , 11, 339-45	12
963	Office-based arthroscopic synovectomy of the wrist in rheumatoid arthritis. 2001 , 17, 884-7	15
962	Etanercept in rheumatoid arthritis. 2001 , 2, 1137-48	66
961	Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. 2001 , 3, 247-52	38
960	Phenotypic characteristics of human monocytes undergoing transendothelial migration. 2001 , 3, 127-32	8
959	Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. 2001 , 27, 427-43	50
958	[Systematic review of clinical trials on the treatment of rheumatoid arthritis with tumour necrosis factor alpha inhibitors]. 2001 , 116, 620-8	
957	Cytokine pathways and joint inflammation in rheumatoid arthritis. 2001 , 344, 907-16	1718
956	CD200 immunoadhesin suppresses collagen-induced arthritis in mice. 2001 , 101, 328-34	79
955	Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis : a therapeutic study using a macrophage-deactivating compound. 2001 , 158, 491-500	37
954	Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. 2001 , 45, 953-6	130
953	Mechanism of action of disease modifying anti-rheumatic agent, gold sodium thiomalate (GSTM). 2001 , 1, 1165-72	12
952	Rheumatoid arthritis. 2001 , 358, 903-11	1051
951	Fármacos inmunomoduladores en patología autoinmune. 2001 , 8, 1743-1748	
950	Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. 2001 , 19, 617-35	82
949	Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. 2001 , 76, 653-6	52

948	A clinical and economic review of disease-modifying antirheumatic drugs. 2001 , 19, 715-28	27
947	A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. 2001 , 19, 1051-64	42
946	Role of B cells in the pathogenesis of rheumatoid arthritis: potential implications for treatment. 2001 , 15, 73-9	19
945	Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience. 2001 , 15, 251-9	30
944	New therapeutic approaches to the management of rheumatoid arthritis. 2001 , 15, 379-93	15
943	Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis. 2001 , 30, 356-9	
942	Human leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies. 2001 , 1, 375-83	7
941	Pharmacotherapeutics: what a difference five decades makes!. 2001 , 174, 48-51	2
940	Current management of rheumatoid arthritis. 2001 , 36, 21-6, 29-30, 35	1
939	Have the new drugs relieved the burden of the orthopedic surgeon?. 2001 , 13, 214-8	2
938	Anti-tumor necrosis factor therapies. 2001 , 13, 164-9	67
937	Fatal Sepsis in a Patient With Rheumatoid Arthritis Treated With Etanercept. 2001 , 76, 653-656	128
936	Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. 2001 , 22, 619-24	40
935	Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 2: the newer drugs and drug strategies. 2001 , 8, 163-79	20
934	Combination therapy in rheumatoid arthritis. 2001 , 23, 165-83	4
933	Extraintestinal Complications of Inflammatory Bowel Disease. 2001 , 4, 227-243	2
932	Radiography of rheumatoid arthritis in the time of increasing drug effectiveness. 2001 , 3, 46-52	8
931	Biliary sepsis in a patient on anti-TNFalpha therapy. 2001 , 170, 210-1	2

930	Anti-TNF agents for rheumatoid arthritis. 2001 , 51, 201-8	85
929	Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-alpha receptor fusion protein. 2001 , 144, 597-600	68
928	Pain management in older adults: prevention and treatment. 2001 , 49, 188-99	134
927	In vitro evaluation of an enhanced human serum amyloid A (SAA2) promoter-regulated soluble TNF receptor fusion protein for anti-inflammatory gene therapy. 2001 , 53, 588-95	6
926	New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. 1999 , 80, 235-50	37
925	Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. 2001 , 44, 61-5	104
924	Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease. 2001 , 44, 739-50	143
923	Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. 2001 , 44, 1149-54	190
922	Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. 2001 , 44, 1215-24	44
921	TIA-1 regulates the production of tumor necrosis factor alpha in macrophages, but not in lymphocytes. 2001 , 44, 2879-87	20
920	Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. 2001 , 19, 163-96	1068
919	Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. 2001 , 19, 153-68	54
918	Cross-talk between glucocorticoid receptor and AP-1. 2001 , 20, 2465-75	184
917	Signal transduction in rheumatoid arthritis. 2001 , 15, 789-803	20
916	The Year in Review: Rheumatology. 2001 , 14, 54-69	
915	Etanercept-induced subacute cutaneous lupus erythematosus. 2001 , 40, 1317-9	104
914	Evidence of IL-18 as a novel angiogenic mediator. 2001 , 167, 1644-53	231
913	Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. 2001 , 60, 660-9	85

912	Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. 2001 , 40, 205-11	394
911	Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. 2001 , 15, 1622-4	138
910	Infliximab treatment for Crohn's disease. 2001 , 77, 436-40	17
909	Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample. 2001 , 60, 956-61	33
908	Etanercept in juvenile rheumatoid arthritis. 2001 , 35, 464-71	17
907	Benchmarking and the percentile assessment of RA: adding a new dimension to rheumatic disease measurement. 2001 , 60, 994-5	5
906	Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. 2001 , 96, 2564-8	66
905	Monoclonal antibody therapy. 2001 , 56, 369-421	9
904	Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. 2001 , 2, 125-37	23
903	Soluble cytokine receptors in biological therapy. 2002 , 2, 585-605	32
902	Cytokines as therapeutic drugs. 2002 , 22, 505-16	37
901	Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. 2002 , 61, 793-8	162
900	Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). 2002 , 61 Suppl 2, ii2-7	44
899	Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. 2002 , 16, 438-40	480
898	Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. 2002 , 11, 753-5	67
897	Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. 2002 , 61 Suppl 3, iii51-60	43
896	Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. 2002 , 61, 960-7	58
895	A small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats. 2002 , 277, 23573-81	69

894	Immune-based therapies: a review of clinical endpoints used in trials of selected immunologic agents. 2002 , 3, 58-88	2
893	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 8-2002. A 56-year-old woman with a persistent left-sided pleural effusion. 2002 , 346, 843-50	5
892	Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. 2002 , 41, 631-7	60
891	Current treatment of juvenile rheumatoid arthritis. 2002 , 109, 109-15	104
890	Anakinra treatment of patients with rheumatoid arthritis. 2002 , 36, 1204-9	23
889	Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. 2002 , 303, 1334-43	105
888	Ankylosing spondylitis: introductory comments on its diagnosis and treatment. 2002 , 61 Suppl 3, iii3-7	33
887	Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. 2002 , 61, 311-8	114
886	Pathogenesis of bone erosions in rheumatoid arthritis. 2002 , 14, 406-10	52
885	Lung injury linked to etanercept therapy. 2002 , 122, 1858-60	116
884	Advances in the medical management of rheumatoid arthritis. 2002 , 63, 294-7	4
883	Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. 2002 , 14, 204-11	107
882	Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. 2002 , 103, 231-42	70
881	Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. 2002 , 25, 173-97	67
880	Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. 2002 , 62, 2493-537	49
879	Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. 2002 , 18, 661-5	42
878	Interferon-beta for treatment of rheumatoid arthritis?. 2002 , 4, 346-52	46
877	Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. 2002 , 4, R7	83

876	Management of Rheumatoid Arthritis. 2002 , 10, 17-39	5
875	Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. 2002 , 346, 1349-56	656
874	The 11th international rheumatology symposium in kobe. <i>Modern Rheumatology</i> , 2002 , 12, 271-85	3.3
873	Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. 2002 , 16, 111-48	71
872	Juvenile rheumatoid arthritis: therapeutic perspectives. 2002 , 4, 335-48	15
871	Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease. 2002 , 2, 215-21	29
870	Immune function in patients with rheumatoid arthritis treated with etanercept. 2002 , 103, 13-21	58
869	Millennium Award. Proteomics for the development of DNA tolerizing vaccines to treat autoimmune disease. 2002 , 103, 7-12	31
868	Anti-CD200R ameliorates collagen-induced arthritis in mice. 2002 , 104, 256-64	54
867	Tumor necrosis factor or tumor promoting factor?. 2002 , 13, 135-41	409
866	Cytokines and anti-cytokine biologicals in autoimmunity: present and future. 2002 , 13, 299-313	139
865	Management of inflammatory arthritis around the elbow. 2002 , 18, 161-8	9
864	Etanercept: A New Drug for the Treatment of Psoriatic Arthritis. 2002 , 8a, 1-5	
863	Etanercept: Dosing, Monitoring and Side Effects. 2002 , 8a, 10-10	
862	Treating rheumatoid arthritis with tumour necrosis factor alpha blockade. 2002 , 324, 312-3	14
861	Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. 2002 , 122, 186-90	41
860	Treating rheumatoid arthritis with new disease modifying drugs. 2002 , 29, 33-5	2
859	Therapy for ankylosing spondylitis: new treatment modalities. 2002 , 16, 631-651	8

858	Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity. 2002 , 46, 2039-44	53
857	Guidelines for the management of rheumatoid arthritis: 2002 Update. 2002 , 46, 328-46	1135
856	Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. 2002 , 46, 1470-9	310
855	Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. 2002 , 46, 1443-50	570
854	Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. 2002 , 46, 2571-3	100
853	Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. 2002 , 46, 3143-50	437
852	Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. 2002 , 46, 755-65	323
851	Experience with etanercept in an academic medical center: are infection rates increased?. 2002 , 47, 17-21	94
850	Efficacy of anakinra in bone: comparison to other biologics. 2002 , 19, 27-39	6
849	Pathogenesis of bone lesions in rheumatoid arthritis. 2002 , 4, 226-31	41
848	Rheumatology, geriatrics, and a way forward. 2002 , 50, 1737-8	2
847	Tumor necrosis factor microsatellite alleles in patients with rheumatoid arthritis in Taiwan. 2002 , 81, 177-82	3
846	Genetic influences on rheumatoid arthritis in African Americans. 2002 , 26, 15-26	1
845	Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. 2003 , 5, 270-7	26
844	Co-morbidity in rheumatoid arthritis. 2003 , 17, 729-52	68
843	Pharmacological treatment of established rheumatoid arthritis. 2003 , 17, 811-29	22
842	The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. 2003 , 48, 1177-89	113
841	Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. 2003 , 48, 1667-75	310

840	Acute injection site reaction to intraarticular etanercept administration. 2003 , 48, 2078-9	26
839	Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. 2003 , 48, 2670-81	157
838	Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. 2003 , 48, 3230-6	607
837	Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. 2003 , 48, 3328-37	86
836	Young women with chronic disease: a female perspective on the impact and management of rheumatoid arthritis. 2003 , 49, 846-52	8
835	Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. 2003 , 27, 375-80	53
834	[Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies]. 2003 , 153, 304-8	0
833	[Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders]. 2003 , 1, 259-72	13
832	Etanercept-induced systemic lupus erythematosus. 2003 , 28, 604-7	50
831	Cytokine-based immunointervention in the treatment of autoimmune diseases. 2003 , 132, 185-92	37
830	Structure-activity relationships of 6-fluoroquinazolines: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation. 2003 , 11, 609-16	25
829	Infection complications associated with the use of biologic agents. 2003 , 29, 185-202	80
828	Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. 2003 , 124, 1774-85	628
827	Quality-of-Life Measurements in Juvenile Rheumatoid Arthritis Patients Treated with Etanercept. 2003 , 23, 511-8	13
826	Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. 2003 , 349, 1907-15	822
825	Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. 2003 , 62, 1168-77	133
824	New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate. 2003 , 29, 481-94, viii	9
823	Psoriasis. 2003 , 361, 1197-204	558

822	[Inhibitors of TNFalpha]. 2003 , 24, 123-6	0
821	Evaluation and management of psoriatic arthritis: the role of biologic therapy. 2003 , 49, S125-32	21
820	Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults. 2003 , 25, 1211-8	21
819	Challenges in assessing costs of rheumatoid arthritis. 2003 , 14, 65-72; quiz 73	
818	The biology of TNF blockade. 2003 , 2, 346-57	81
817	Etanercept for the treatment of rheumatoid arthritis. 2003 , CD004525	48
816	Current treatment of psoriatic arthritis. 2003 , 29, 495-511	8
815	Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. 2003 , 17, 139-45	9
814	Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. 2003 , 17, 425-31	59
813	Number needed to treat (NNT): implication in rheumatology clinical practice. 2003 , 62, 316-21	52
812	Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. 2003 , 62 Suppl 2, ii30-3	51
811	Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). 2003 , 62 Suppl 2, ii2-9	35
810	Does etanercept induce uveitis?. 2003 , 87, 925	74
809	Etanercept as monotherapy in patients with psoriasis. 2003 , 349, 2014-22	978
808	Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. 2003 , 62, 1128-32	52
807	Glucocorticoids in the treatment of early and late RA. 2003 , 62, 1033-7	63
806	New concepts in the treatment of rheumatoid arthritis. 2003 , 54, 197-216	58
805	Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. 2003 , 2, 347-65	14

804	New perspectives and emerging therapies for immune-mediated inflammatory disorders. 2003 , 26, 319-25	8
803	Differentiating the new rheumatoid arthritis biologic therapies. 2003 , 9, 99-114	17
802	Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. 2003 , 124, 177-85	311
801	Synthesis and evaluation of 6-nitro-7-(1-piperazino)quinazolines: dual-acting compounds with inhibitory activities toward both tumor necrosis factor-alpha (TNF-alpha) production and T cell proliferation. 2003 , 51, 1109-12	2
800	Psoriatic Arthritis: Current Treatment Options. 2003 , 9a, 4-6	
799	Subsidised access to TNF-inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?. 2004 , 181, 457-458	5
798	The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. 2004 , 5, 581-94	73
797	Two inhibitors of DNA-synthesis lead to inhibition of cytokine production via a different mechanism. 2004 , 23, 1089-100	8
796	Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. 2005 , 64, 403-7	165
795	Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. 2004 , 63, 1594-600	214
794	Monoclonal antibody therapy in lymphoid leukemias. 2004 , 51, 127-67	2
793	Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. 2004 , 63, 1538-43	111
792	Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. 2004 , 63, 769-73	85
791	TNFalpha therapy in psoriatic arthritis and psoriasis. 2004 , 63, 755-8	76
790	Antibody-cytokine fusion proteins for the therapy of cancer. 2005 , 109, 347-74	14
789	Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. 2004 , 63, 1075-8	75
788	Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. 2004 , 63 Suppl 2, ii13-ii17	45
787	Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. 2004 , 173, 5818-26	115

786	A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. 2004 , 99, 255-60	95
785	Nonsteroidal Antiinflammatory Drugs. 2004 , 337-376	
784	Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. 2004 , 63 Suppl 2, ii2-ii12	41
783	Biologics in combination with nonbiologics: efficacy and safety. 2004 , 17, 432-40	30
782	Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. 2004 , 57, 790-7	17
781	Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. 2004 , 58, 201-8	18
780	Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. 2004 , 20, 1337-46	104
779	Biological response modifiers. 2004 , 7, 179-183	1
778	The use of methotrexate in rheumatoid arthritis. 2004 , 34, 465-83	87
777	Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. 2004 , 5, 36	46
776	Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients. 2004 , 71, 601-3	19
775	Tumour necrosis factor-alpha mediates neutrophil migration to the knee synovial cavity during immune inflammation. 2004 , 496, 197-204	35
774	The usefulness and the limitations of animal models in identifying targets for therapy in arthritis. 2004 , 18, 47-58	26
773	The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. 2004 , 18, 59-80	61
772	Glucocorticoids in rheumatoid arthritis: a senescent research agenda on the brink of rejuvenation?. 2004 , 18, 21-9	5
771	Adalimumab dans la polyarthrite rhumatoïde : à propos de 18 cas de switch après échec ou intolérance d'un ou des deux autres anti TNF. 2004 , 71, 1219-1220	
770	Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. 2004 , 31, 463-90	23
769	Response of TNF-hyporesponsive SPRET/Ei mice in models of inflammatory disorders. 2004 , 15, 537-43	5

768	Infliximab in rheumatoid arthritis. 2004 , 6, 334-5	3
767	Traitement de la polyarthrite rhumatoïde par l'etanercept en cas de réponse inadéquate ou d'intolérance au méthotrexate. 2004 , 71, S49-S56	
766	Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. 2004 , 50, 353-63	231
765	Novel tumor necrosis factor alpha-regulated genes in rheumatoid arthritis. 2004 , 50, 420-31	66
764	A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. 2004 , 50, 985-98	120
763	A TNFR1 genotype with a protective role in familial rheumatoid arthritis. 2004 , 50, 413-9	25
762	Documenting damage progression in a two-year longitudinal study of rheumatoid arthritis patients with established disease (the DAMAGE study cohort): is there an advantage in the use of magnetic resonance imaging as compared with plain radiography?. 2004 , 50, 1383-9	24
761	Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. 2004 , 50, 1761-9	665
760	Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. 2004 , 50, 2264-72	721
759	Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology. 2004 , 50, 3334-45	50
758	Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. 2004 , 50, 3432-43	948
757	Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. 2004 , 50, 3408-17	244
756	Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. 2004 , 51, 964-73	40
755	Design and engineering human forms of monoclonal antibodies. 2004 , 61, 121-136	17
754	Pharmacogenetics of inflammatory bowel disease. 2004 , 18, 597-609	1
753	Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. 2004 , 3, 391-403	53
752	Pursuit of optimal outcomes in rheumatoid arthritis. 2004 , 22, 13-26	13
751	Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis. 2004 , 22, 107-32	17

750	Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis. 2004 , 22, 1071-95	12
749	Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. 2004 , 5, 385-94	29
748	Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. 2004 , 6, 137-46	39
747	Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis. 2004 , 5, 1881-6	15
746	Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. 2004 , 63, 508-16	44 ^o
745	Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. 2004 , 22, 39-53	49
744	Appropriate and effective management of rheumatoid arthritis. 2004 , 63, 627-33	65
743	Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. 2004 , 22, 477-86, x	22
742	[Respiratory complications of new treatments for rheumatoid arthritis]. 2004 , 21, 1107-15	18
741	[Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab]. 2004 , 122, 321-4	4
740	Treatment of rheumatoid arthritis with etanercept. 2004 , 30, 311-28, vi-vii	18
739	Health services research in rheumatology: a great deal accomplished, a great deal left to do. 2004 , 30, 879-98, viii	
738	The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. 2004 , 22, 449-59, ix	33
737	New drugs for rheumatoid arthritis. 2004 , 350, 2167-79	527
736	Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. 2004 , 64, 1267-83	61
735	Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position. 2004 , 47, 6311-25	145
734	Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. 2004 , 6, R239-49	108
733	Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. 2004 , 6, R264-72	112

732	Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?. 2004 , 6 Suppl 2, S3-S11	18
731	Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. 2004 , 28, 67-74	80
730	Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis. 2004 , 28, 158-61	3
729	Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. 2004 , 22, 3144-53	24
728	Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. 2004 , 51, 580-4	104
727	Serious infections associated with anticytokine therapies in the rheumatic diseases. 2004 , 19, 320-34	93
726	Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. 2004 , 363, 675-81	1454
725	Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction. 2004 , 116, 14-6, 21-4	5
724	Sepsis as a possible adverse drug reaction in patients with rheumatoid arthritis treated with TNFalpha antagonists. 2004 , 10, 119-22	12
723	Bone loss in inflammatory arthritis: mechanisms and treatment strategies. 2004 , 16, 419-27	88
722	Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. 2004 , 10, 50-2	19
721	Etanercept [review of efficacy and safety after five years of clinical use. 2004 , 1, 11-23	3
720	Review of immunosuppressive drug therapy in uveitis. 2004 , 15, 293-8	21
719	Blocking the effect of interleukin-1 and tumor necrosis factor in rheumatoid arthritis is well tolerated and effective. 2004 , 1, 255-266	
718	TNF inhibitors: a new age in rheumatoid arthritis treatment. 2004 , 104, 60-8; quiz 68-9	42
717	[Recent development of new drugs for the treatment of allergic diseases]. 2004 , 123, 335-48	
716	The additive role of innate and adaptive immunity in the development of arthritis. 2004 , 327, 196-201	6
715	[Focus on biological agents in rheumatoid arthritis: newer treatments and therapeutic strategies]. 2004 , 59, 451-61	4

714	Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. 2005 , 11, 47-9	34
713	The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis. 2005 , 23, 289-98	14
712	IL-13/IL-13 Receptor Interaction, an Emerging Therapeutic Target in Allergic Disease. 2005 , 54, 229-233	3
711	Disseminated Tuberculosis and Lung Cancer Associated With Infliximab Treatment of Rheumatoid Arthritis. 2005 , 12, 115-120	
710	Anti-TNF Biological Agents in Rheumatoid Arthritis and Other Inflammatory Diseases. 2005 , 54, 191-202	9
709	Influence des pratiques médicales sur les coûts de traitement de la polyarthrite rhumatoïde par biothérapie anti-TNFα en France. 2005 , 72, 1306-1313	2
708	[Four-year observation of etanercept therapy for rheumatoid arthritis in a single German center]. 2005 , 64, 265-73	1
707	[Prescription of glucocorticoids by rheumatologists in patients with rheumatoid arthritis in Germany]. 2005 , 64, 149-54	1
706	Toll-like receptors and rheumatoid arthritis: is there a connection?. 2006 , 19-40	2
705	The presence of cytokine-suppressive CD4+CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis. 2005 , 62, 312-7	57
704	Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. 2005 , 153, 417-23	39
703	A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. 2005 , 152, 1304-12	586
702	New therapies for rheumatoid arthritis. 2005 , 140, 195-204	65
701	Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy. 2005 , 18, 651-5	42
700	Etanercept in arthritis. 2005 , 59, 114-8	12
699	R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models. 2005 , 506, 285-95	34
698	Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. 2005 , 516, 282-9	104
697	Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France. 2005 , 72, 550-6	22

696	[Pharmaceutical care of patients with rheumatoid and psoriatic arthritis receiving etanercept]. 2005 , 29, 171-6	6
695	The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. 2005 , 34, 819-36	171
694	Differentiating the efficacy of the tumor necrosis factor inhibitors. 2005 , 34, 7-11	71
693	Diet and rheumatoid arthritis: a review of the literature. 2005 , 35, 77-94	98
692	Infections associated with tumor necrosis factor-alpha antagonists. 2005 , 25, 1181-92	94
691	Impact of managed care on the use of biologic agents for rheumatoid arthritis. 2005 , 53, 423-30	7
690	Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. 2005 , 53, 337-42	67
689	Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. 2005 , 52, 2192-201	151
688	Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. 2005 , 52, 2616-24	98
687	Infections in patients with rheumatoid arthritis treated with biologic agents. 2005 , 52, 3403-12	526
686	Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. 2005 , 53, 740-7	43
685	Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. 2005 , 7, 3-9	15
684	Role of biological agents in immune-mediated inflammatory diseases. 2005 , 98, 192-204	31
683	Tumour necrosis factor inhibitors. 2005 , 183, 205-8	90
682	Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugs. 2005 , 76, 614-9	10
681	Tumor necrosis factor inhibition and opportunistic infections. 2005 , 41 Suppl 3, S187-8	13
680	Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. 2005 , 64, 1557-62	120
679	Treatment continuation in patients receiving biological agents or conventional DMARD therapy. 2005 , 64, 1274-9	103

678 B Psoriatic Arthritis. **2005**, 223-243

677 Quality of life and costs for different treatment strategies for rheumatoid arthritis. **2005**, 5, 395-410

3

676 Etanercept: an introduction. *Expert Review of Clinical Immunology*, **2005**, 1, 313-23

5.1

2

675 Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. **2005**, 64 Suppl 4, iv2-14

92

674 Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. **2005**, 64, 1003-8

21

673 Rheumatoid arthritis: an overview of new and emerging therapies. **2005**, 45, 751-62

114

672 Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. **2005**, 64, 839-44

80

671 Psoriatic arthritis treatment: biological response modifiers. **2005**, 64 Suppl 2, ii78-82

34

670 A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. **2005**, 5, 519-29

4

669 Pharmacokinetics, efficacy, and safety of short-term (12 weeks) etanercept for methotrexate-refractory polyarticular juvenile idiopathic arthritis in Japan. *Modern Rheumatology*, **2005**, 15, 397-404

3.3

7

668 A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. **2005**, 64, 64-9

71

667 IKK{beta} as a target for treatment of inflammation induced bone loss. **2005**, 64 Suppl 4, iv81-5

17

666 Anti-tumour necrosis factor alpha therapy: can we afford it?. **2005**, 64, 969-70

5

665 Immunological therapies for rheumatoid arthritis. **2005**, 73-74, 71-82

13

664 Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12. **2005**, 64, 537-43

35

663 Etanercept for Refractory Ocular Sarcoidosis. **2005**, 128, 1062-1067

148

662 Treatment of Rheumatoid Arthritis in the Elderly. **2005**, 35, 151-154

661 Tratamiento biológico de las enfermedades reumáticas. **2005**, 9, 1830-1839

660	Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. 2005 , 64, 995-1002	82
659	Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. 2005 , 34, 353-8	106
658	The use of systemic immune moderators in dermatology: an update. 2005 , 23, 259-300	43
657	L'expérience d'un anti-TNF en rhumatologie. 2005 , 132, 10-12	
656	T cell targeted immunotherapy for autoimmune disease. 2005 , 38, 577-96	4
655	Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors?. 2005 , 19, 211-31	51
654	Use of etanercept in the dermatology setting. A review. 2005 , 6, 49-59	11
653	Blockade of TNF does not alter oxygen burst and phagocytosis of human neutrophils in patients with rheumatoid arthritis. 2005 , 209, 669-79	10
652	The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. 2005 , 24, 52-7	31
651	Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. 2005 , 65, 661-94	77
650	Optic neuritis with concurrent etanercept and isoniazid therapy. 2005 , 39, 2131-5	32
649	Monoclonal antibodies and fusion proteins in medicine. 2005 , 116, 721-9; quiz 730	31
648	Novel therapies for rheumatoid arthritis. 2005 , 12, 217-25	7
647	Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. 2005 , 7, R666-76	177
646	Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. 2006 , 8, R174	118
645	Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. 2006 , 8, R112	34
644	Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register. 2006 , 8, R66	116
643	Chapter 17 Cytokines and pain. 2006 , 81, 231-48	4

642	Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients. 2006 , 23, 855-60	19
641	Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. 2006 , 23, 167-78	25
640	Artritis reumatoide del adulto: tratamiento. 2006 , 39, 1-26	
639	The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis. 2006 , 24, 1011-20	17
638	Valutazione economica di etanercept nel trattamento dell'Artrite Reumatoide. 2006 , 8, 129-140	
637	[Not Available]. 2006 , 2, 78-89	9
636	Papel de los tratamientos de fondo en las artropatías inflamatorias. 2006 , 10, 1-6	
635	Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared?. 2006 , 32 Suppl 1, 21-8	9
634	Treatment of rheumatoid arthritis. 2006 , 63, 2451-65	118
633	A new generation of high-affinity humanized PEGylated Fab η fragment anti-tumor necrosis factor- β monoclonal antibodies. 2006 , 3, 535-545	35
632	Tumor necrosis factor inhibitors for rheumatoid arthritis. 2006 , 355, 704-12	372
631	Rheumatoid Arthritis. 2006 ,	
630	Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. 2006 , 140, 777-83	32
629	Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. 2006 , 17, 9-17	99
628	«Anticorps anti-TNF, quelles applications, quels effets secondaires?». 2006 , 46, 261-266	1
627	[Monoclonal antibodies in the treatment of rheumatoid arthritis: toward a therapeutic revolution]. 2006 , 329, 228-40	3
626	Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. 2006 , 54, S92-100	59
625	Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. 2006 , 54, S112-9	38

624	Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. 2006 , 54, S101-11	76
623	Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. 2006 , 21, 946-9	23
622	Etanercept in Rheumatoid Arthritis: Long Term Anti-Inflammatory Efficacy in Clinical Practice. 2006 , 4, 171-176	1
621	Inflammatory arthritides of the spine: surgical versus nonsurgical treatment. 2006 , 443, 208-21	12
620	Place des traitements de fond dans la prise en charge des rhumatismes inflammatoires. 2006 , 1, 1-6	
619	Polyarthrite rhumatoïde de l'adulte: traitement. 2006 , 1, 1-23	1
618	The emerging use of TNF-alpha inhibitors in orbital inflammatory disease. 2006 , 46, 165-81	22
617	Emerging new therapies in rheumatoid arthritis: what's next for the patient?. 2006 , 29, 326-37	5
616	Interleukin-6 in rheumatoid arthritis. 2006 , 18, 277-81	131
615	Experience of antitumor necrosis factor- α therapies in Taiwan. 2006 , 9, 161-164	1
614	Anti-tumor necrosis factor therapy: the Australian experience. 2006 , 9, 119-123	2
613	A practical guide for the use of biologic agents in the treatment of rheumatoid arthritis*. 2006 , 9, 123-126	1
612	Treatment of inflammatory dermatoses by tumour necrosis factor antagonists. 2006 , 20, 1171-87	19
611	Etanercept for the treatment of severe childhood psoriasis. 2006 , 154, 181-3	34
610	Etanercept: effective in the management of hidradenitis suppurativa. 2006 , 154, 726-9	110
609	Treatment of erythrodermic psoriasis with etanercept. 2006 , 155, 156-9	42
608	A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics. 2006 , 12, 463-70	14
607	Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. 2006 , 62, 435-45	34

606	Recommandations de la Société française de rhumatologie pour l'utilisation des agents anti-TNF chez les personnes souffrant de polyarthrite rhumatoïde. 2006 , 73, 726-735	
605	DHEA metabolism in arthritis: a role for the p450 enzyme Cyp7b at the immune-endocrine crossroad. 2006 , 1069, 401-13	13
604	Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis. 2006 , 1069, 428-37	31
603	Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. 2006 , 26, 741-8	17
602	Sjögren syndrome in a child: favorable response of the arthritis to TNFalpha blockade. 2006 , 25, 746-8	17
601	Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. 2007 , 26, 211-5	112
600	Immunogenicity, efficacy and adverse events of adalimumab in RA patients. 2007 , 27, 269-74	116
599	[S3-Guidelines for the therapy of psoriasis vulgaris]. 2006 , 4 Suppl 2, S1-126	58
598	Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis. 2006 , 73, 433-41	35
597	Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938. 2006 , 534, 241-9	35
596	[Effectiveness and safety of adalimumab and etanercept for rheumatoid arthritis in a third-level hospital]. 2006 , 30, 223-9	3
595	The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. 2006 , 54, 600-6	103
594	Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. 2006 , 54, 1063-74	407
593	Infliximab treatment maintains employability in patients with early rheumatoid arthritis. 2006 , 54, 716-22	86
592	Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). 2006 , 54, 1122-31	273
591	Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. 2006 , 54, 1786-94	114
590	Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. 2006 , 55, 287-93	41
589	Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. 2006 , 54, 1987-94	147

588	Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. 2006 , 54, 2368-76	587
587	Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha. 2006 , 54, 2872-85	25
586	Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. 2006 , 54, 3399-407	160
585	Infliximab for rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2006 , 2, 193-207	5.1 5
584	Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. 2006 , 65, 1602-7	30
583	Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. 2006 , 65, 1478-83	100
582	Combination therapy with acitretin for psoriasis. 2006 , 17, 108-11	9
581	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. 2006 , 65 Suppl 3, iii2-15	50
580	Long term safety of etanercept in elderly subjects with rheumatic diseases. 2006 , 65, 379-84	100
579	Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. 2006 , 45, 558-65	40
578	Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. 2006 , 65, 1572-7	81
577	A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors. 2007 , 66, 124-7	13
576	The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. 2006 , 65, 35-9	83
575	Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. 2006 , 65, 328-34	64
574	Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept. 2006 , 65, 1649-52	9
573	Macrophage migration inhibitory factor and glucocorticoid sensitivity. 2006 , 45, 937-43	47
572	A role for transcription factor NF-kappaB in autoimmunity: possible interactions of genes, sex, and the immune response. 2006 , 30, 152-8	51
571	Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. 2007 , 66, 228-34	197

570	InforMatrix: treatment of rheumatoid arthritis using biologicals. 2006 , 7, 1769-89		2
569	Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. 2006 , 65, 1357-62		81
568	A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. 2006 , 65, 1578-84		61
567	Safety of extended treatment with anakinra in patients with rheumatoid arthritis. 2006 , 65, 1006-12		211
566	Leflunomide in the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2006 , 2, 17-31	5.1	7
565	Toll-like receptors: a new target in rheumatoid arthritis?. <i>Expert Review of Clinical Immunology</i> , 2006 , 2, 585-99	5.1	18
564	Antibody Molecules, Genetic Engineering of. 2006 ,		
563	Tacrolimus in rheumatoid arthritis. 2006 , 7, 91-8		16
562	Mechanism of Action, Pharmacokinetics, and Drug Interactions of Etanercept in Dermatology. 2007 , 11, S3-S13		1
561	Parapharyngeal abscess in a patient receiving etanercept. 2007 , 41, 341-4		6
560	Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. 2007 , 83, 251-60		199
559	Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. 2007 , 66, 664-9		36
558	Etanercept attenuates the development of cerulein-induced acute pancreatitis in mice: a comparison with TNF-alpha genetic deletion. 2007 , 27, 542-51		30
557	Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis. 2007 , 8, 1373-97		7
556	Splanchnic ischemia and reperfusion injury is reduced by genetic or pharmacological inhibition of TNF-alpha. 2007 , 81, 1032-43		25
555	The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. 2007 , 66, 1473-8		139
554	What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. 2007 , 66, 1132-6		89
553	Cost-effectiveness of tumor necrosis factor-alpha antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. 2007 , 7, 155-69		2

552	Indian herbal medicines: possible potent therapeutic agents for rheumatoid arthritis. 2007 , 41, 12-7	45
551	[Cost of rheumatoid arthritis in france: comparison leflunomide/etanercept]. 2007 , 62, 137-42	3
550	Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. 2007 , 7, 393-403	33
549	Interleukin-1 in Rheumatoid Arthritis: Its Inhibition by IL-1Ra and Anakinra. 2007 , 23, 86-94	2
548	Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. 2007 , 56, 509-17	134
547	Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study. 2007 , 29, 1071-85	9
546	Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. 2007 , 60, 397-409	130
545	A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. 2007 , 56, 598-603	123
544	Critical appraisal of pharmacoeconomic studies comparing TNF-alpha antagonists for rheumatoid arthritis treatment. 2007 , 7, 613-26	3
543	Gene therapy with an improved doxycycline-regulated plasmid encoding a tumour necrosis factor-alpha inhibitor in experimental arthritis. 2007 , 9, R7	22
542	Tumor necrosis factor as a therapeutic target of rheumatologic disease. 2007 , 11, 1369-84	45
541	The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. 2007 , 36, 411-7	50
540	Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. 2007 , 24, 239-54	46
539	The direct medical cost of rheumatoid arthritis in Hong Kong. 2007 , 10, 443-453	1
538	Abatacept: a novel treatment for rheumatoid arthritis. 2007 , 8, 2371-9	7
537	The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. 2007 , 8, 2089-107	56
536	Adalimumab in the therapy of uveitis in childhood. 2007 , 91, 319-24	207
535	Rheumatoid arthritis. 2007 , 12, 525-37, vii	11

534	Etanercept: a review of its use in the management of rheumatoid arthritis. 2007 , 67, 1211-41	36
533	Review of Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis. 2007 , 14, 1	9
532	Biological Macromolecules. 2007 , 431-447	0
531	Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. 2007 , 56, 13-20	328
530	Effects of infliximab therapy on gene expression levels of tumor necrosis factor alpha, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R in patients with rheumatoid arthritis. 2007 , 56, 2160-9	14
529	Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. 2007 , 56, 2905-12	427
528	Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. 2007 , 57, 1514-9	39
527	Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. 2007 , 56, 3928-39	171
526	Infliximab et polyarthrite rhumatoïde: quels résultats à long terme? Expérience pragmatique du réseau hospitalier Nord-Pas-de-Calais. 2007 , 74, 61-65	
525	Maintien thérapeutique des trois anti-TNF disponibles, dans la polyarthrite rhumatoïde (PR), la spondylarthrite ankylosante (SA) et le rhumatisme psoriasique (RP): à propos de 571 prescriptions d'anti-TNF chez 442 patients sur une période de six ans. 2007 , 74, 242-249	
524	Traitement anti-TNF en clinique courante. Efficacité sur trois ans chez des patients atteints de polyarthrite rhumatoïde. 2007 , 74, 1276-1282	
523	Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. 2007 , 26, 1237-54	110
522	Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database. 2007 , 37, 591-600	29
521	Two years of experience with etanercept in recalcitrant psoriasis. 2007 , 156, 1010-4	27
520	Severe psoriasis pustulosa palmaris et plantaris (Barber-Kligsbeck) treated successfully with soluble tumour necrosis factor receptor fusion protein (etanercept). 2007 , 21, 255-7	9
519	Role of tumor necrosis factor-alpha in rheumatoid arthritis: a review. 2007 , 10, 270-274	56
518	Abatacept in the treatment of rheumatoid arthritis. 2007 , 61, 494-500	16
517	Biological and clinical effects of anti-TNFalpha treatment. 2007 , 7, 35-41	94

516	Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network. 2007 , 74, 56-9	16
515	TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. 2007 , 74, 148-54	60
514	Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis. 2007 , 74, 606-11	7
513	Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. 2007 , 5 Suppl 3, 1-119	75
512	[Cytokines]. 2007 , 66, 297-8, 300-3	2
511	New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval. 2007 , 63, 879-89	12
510	Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. 2007 , 27, 793-806	73
509	Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. 2007 , 26, 787-8	32
508	Off-target activity of TNF-alpha inhibitors characterized by protein biochips. 2008 , 391, 1713-20	21
507	Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. 2008 , 28, 261-9	16
506	Infection of an urachal cyst during etanercept therapy in juvenile idiopathic arthritis. 2008 , 28, 819-22	4
505	Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. 2008 , 28, 1031-4	22
504	Biologicals in rheumatology: Austrian experiences from a rheumatic outpatient clinic. 2008 , 29, 69-73	2
503	The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. 2008 , 8 Suppl 2, 95-106	27
502	Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. 2008 , 58, 667-77	166
501	Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. 2008 , 58, 964-75	212
500	Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. 2008 , 58, 1921-30	66
499	Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. 2008 , 59, 515-22	236

498	Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. 2008 , 58, 2248-56	208
497	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. 2008 , 59, 762-84	1118
496	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. 2008 , 58, 3319-29	458
495	Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: a systematic review. 2008 , 59, 1625-38	34
494	Modèle d'impact budgétaire du rituximab utilisé après échec d'un ou de plusieurs agents anti-TNFα dans le traitement de la polyarthrite rhumatoïde. 2008 , 75, 1229-1236	
493	Etanercept treatment in myasthenia gravis. 2008 , 1132, 300-4	18
492	Biologic treatments for systemic rheumatic diseases. 2008 , 14, 206-16	15
491	Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. 2008 , 9, 52	166
490	TNFalpha blockade in human diseases: an overview of efficacy and safety. 2008 , 126, 13-30	194
489	TNFalpha blockade in human diseases: mechanisms and future directions. 2008 , 126, 121-36	218
488	Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. 2008 , 75, 688-95	21
487	Drug-induced arthritic and connective tissue disorders. 2008 , 38, 249-64	21
486	Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis. 2008 , 24, 733-43	126
485	Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists. 2008 , 68, 591-606	21
484	Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. 2008 , 68, 747-70	21
483	A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. 2008 , 135, 1953-60	229
482	Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. 2008 , 10, R94	126
481	Update on the natural history and systemic treatment of psoriasis. 2008 , 24, 171-96	26

480	Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. 2008 , 121, 532-8	30
479	Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. 2008 , 106, 778-87	25
478	[Infections in Patients With Rheumatoid Arthritis Undergoing Anti-TNF- α Drug Therapy]. 2008 , 4 Suppl 2, 18-23	3
477	Psychological adjustment to chronic disease. 2008 , 372, 246-55	383
476	Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy. 2008 , 83, 181-194	40
475	Effects of alpha-glucosylhesperidin, a bioactive food material, on collagen-induced arthritis in mice and rheumatoid arthritis in humans. 2008 , 30, 117-34	38
474	Assessment of anti-TNF- α efficacy in rheumatoid arthritis: is 3 months sufficient?. 2008 , 47, 1073-6	7
473	The Development of Novel Therapies for Rheumatoid Arthritis. 2008 , 18, 723-738	129
472	Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. 2008 , 7, 411-9	46
471	Orbital sarcoid treatment. 2008 , 3, 219-227	
470	The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. 2008 , 112, 3073-81	103
469	Etanercept-induced lupus erythematosus presenting as a unilateral pleural effusion. 2008 , 134, 850-853	15
468	Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy. 2008 , 83, 181-194	245
467	Rate and causes of infliximab discontinuation in patients with rheumatoid arthritis in a private clinical practice. 2008 , 14, 313-7	4
466	Update on the use of etanercept across a spectrum of rheumatoid disorders. 2008 , 2, 165-73	8
465	Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. 2008 , 2, 229-52	16
464	Monoclonal antibodies and fusion proteins. 2008 , 1405-1416	
463	Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis. 2009 , 1, 17-35	3

462	Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. 2009 , 1, 163-178		3
461	Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. 2010 , 4, 159-70		20
460	Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. 2009 , 68, 789-96		391
459	Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. 2009 , 68, 805-11		241
458	A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. 2009 , 181, 787-96		177
457	Mycobacterium heckeshornense lumbar spondylodiskitis in a patient with rheumatoid arthritis receiving etanercept treatment. <i>Journal of Rheumatology</i> , 2009 , 36, 2130-1	4.1	14
456	Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. 2009 , 68, 209-15		165
455	Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. 2009 , 43, 967-72		24
454	Certolizumab pegol for rheumatoid arthritis: effective in combination with methotrexate or as monotherapy. 2009 , 4, 253-266		3
453	Therapeutic options for rheumatoid arthritis. 2009 , 10, 2095-106		24
452	Assessing adequate treatment response in patients with rheumatoid arthritis. 2009 , 31, 1219-31		7
451	Predicting response to anti-TNF treatment in rheumatoid arthritis patients. 2009 , 8, 431-7		47
450	Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. 2009 , 76, 248-53		35
449	Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. 2009 , 61, 560-8		150
448	Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. 2009 , 60, 1232-41		182
447	Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening		35
446	Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. 2009 , 18, 1195-205		334
445	The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. 2009 , 18, 1195-205		41

444	Limits of add-on trials: antirheumatic drugs. 2009 , 65, 33-41	7
443	Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. 2009 , 8, 150-62	7
442	The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. 2009 , 8, 371-89	15
441	A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. 2009 , 70, 337-44	23
440	Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. 2009 , 161, 1081-8	115
439	Recall injection-site reactions to etanercept in a patient with psoriasis. 2009 , 34, 414-5	3
438	Suppression of complete Freund's adjuvant-induced adjuvant arthritis by cobratoxin. 2009 , 30, 219-27	54
437	Cytokines as targets for anti-inflammatory agents. 2009 , 1182, 88-96	8
436	Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. 2009 , 23, 595-600	29
435	The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. 2009 , 30, 6638-47	46
434	Étude de cohorte prospective des effets de l'infliximab sur le facteur rhumatoïde, les anticorps anti-peptides cycliques citrullinés et les anticorps antinucléaires chez les patients ayant une polyarthrite rhumatoïde ancienne. 2009 , 76, 410-416	1
433	Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. 2009 , 68, 25-32	356
432	[Anti-TNF drugs: New results on efficacy]. 2009 , 5 Suppl 1, 71-6	3
431	Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. 2009 , 23, 111-24	58
430	Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. 2009 , 69, 1403-15	72
429	Randomized controlled trial design in rheumatoid arthritis: the past decade. 2009 , 11, 205	29
428	Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety. 2009 , 26, 647-64	18
427	Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. 2009 , 26, 273-93	19

426	Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis. 2009 , 38, 439-44	14
425	Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. 2009 , 25, 1131-42	26
424	Stakeholder Satisfaction with the Australian Rheumatology Association Database (ARAD). 2009 , 2, 61-8	1
423	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. 2009 , 374, 210-21	416
422	Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. 2009 , 19, 319-23	26
421	Urticaria due to etanercept in a patient with psoriatic arthritis. 2009 , 102, 304-5	7
420	Fish oil and rheumatoid arthritis: past, present and future. 2010 , 69, 316-23	62
419	Sequential use of biologic therapy in rheumatoid arthritis. 2010 , 22, 321-9	22
418	Tumor necrosis alpha-blocking agent (etanercept): a triple blind randomized controlled trial of its use in treatment of sciatica. 2010 , 23, 74-7	40
417	Immunotherapy of rheumatoid arthritis targeting inflammatory cytokines and autoreactive T cells. 2010 , 58, 27-36	20
416	Tumor Necrosis Factor Inhibitors and Fungal Infections. 2010 , 4, 38-45	5
415	Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. 2010 , 39, 425-41	75
414	Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. 2010 , 30, 339-53	82
413	Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. 2010 , 62, 3154-60	50
412	No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. 2010 , 62, 3145-53	58
411	Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profiles. 2010 , 20, 828-31	11
410	Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis. 2010 , 45, 1227-50	36
409	rSj16, a recombinant protein of Schistosoma japonicum-derived molecule, reduces severity of the complete Freund's adjuvant-induced adjuvant arthritis in rats' model. 2010 , 32, 739-48	32

408	TNF receptor 2 pathway: drug target for autoimmune diseases. 2010 , 9, 482-93		289
407	New and emerging therapies for the treatment of rheumatoid arthritis. 2010 , 2, 35-43		7
406	The Incidence of Serious Infection among Rheumatoid Arthritis Patients Exposed to Tumor Necrosis Factor Antagonists. 2010 , 17, 246		3
405	[Tuberculosis in rheumatoid arthritis patients: the difficulty in making the diagnosis of latent infection]. 2010 , 36, 243-51		3
404	Prefilled certolizumab pegol (Cimzia(fi)) syringes for self-use in the treatment of rheumatoid arthritis. 2010 , 3, 25-31		2
403	Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. 2010 , 4, 263-78		64
402	Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations. 2010 , 2, 101-19		4
401	Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. <i>Journal of Rheumatology</i> , 2010 , 37, 1221-7	4.1	42
400	Clinically validated approaches to the treatment of autoimmune diseases. 2010 , 19, 195-213		21
399	New biologic for treating rheumatoid arthritis: clinical trial experience with tocilizumab. 2010 , 5, 17-24		
398	[Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: effectiveness comparative study]. 2010 , 134, 665-70		5
397	[Quality of storage of thermolabile drugs in patients' homes]. 2010 , 25, 64-9		10
396	Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. 2010 , 13, 12-26		17
395	Certolizumab pegol: a new biologic targeting rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010 , 6, 855-66	5.1	15
394	The efficacy and safety of golimumab in the treatment of arthritis. 2010 , 10, 1131-43		2
393	Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. 2010 , 12, R147		55
392	Novel TNF antagonists for the treatment of rheumatoid arthritis. 2010 , 19, 105-15		11
391	Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan. <i>Modern Rheumatology</i> , 2010 , 20, 107-113	3.3	7

390	Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. 2010 , 10, 1105-12		5
389	Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics. 2011 , 27, 71-8		17
388	Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept. 2011 , 40, 183-91		7
387	Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. <i>Journal of Rheumatology</i> , 2011 , 38, 1273-81	4.1	67
386	Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. 2011 , 137, 533-40		56
385	Adverse effects of biologics: a network meta-analysis and Cochrane overview. 2011 , CD008794		353
384	Serum cytokine concentrations in a patient with rheumatoid arthritis on etanercept therapy who subsequently developed pneumocystis pneumonia: a case report. 2011 , 2011, 185657		2
383	New therapies in the management of rheumatoid arthritis. 2011 , 23, 245-51		54
382	Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine. 2011 , 36, 2158-67		17
381	New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade. 2011 , 34, 107-15		1
380	Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. <i>Journal of Rheumatology</i> , 2011 , 38, 990-6	4.1	38
379	Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management. 2011 , 171, 657-67		8
378	Advances in the development and application of biological therapies for rheumatoid arthritis: review of the latest clinical evidence. 2011 , 1, 557-573		
377	Biologic monotherapy for the treatment of rheumatoid arthritis. 2011 , 1, 1291-1300		3
376	Certolizumab pegol for the treatment of rheumatoid arthritis. 2011 , 8, 391-402		
375	Interpreting clinical trial results for moderate-to-severe rheumatoid arthritis: practical applications for rheumatology healthcare providers. 2011 , 23, 479-92		1
374	Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. 2011 , 31, 39-51		45
373	Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. 2011 , 33, 679-707		185

372	Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. 2011 , 10, 617-23	59
371	Anti-TNF therapy. 2011 , 25, 549-67	100
370	Immune modulation of rheumatoid arthritis. 2011 , 25, 873-89	6
369	A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. 2011 , 27, 1885-97	35
368	Wirkungen und Interaktionen der Biologika. 2011 , 10, 12-16	
367	Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association. 2011 , 16, 778-84	24
366	Cytokine modulators in the treatment of sarcoidosis. 2011 , 31, 1539-44	13
365	Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. 2011 , 63, 65-78	62
364	Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. 2011 , 63, 512-21	62
363	Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. 2011 , 63, 1479-85	111
362	Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. 2011 , 70, 1831-4	46
361	Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis. 2011 , 51, 864-75	13
360	Anti-inflammatory properties of Septilin in lipopolysaccharide activated monocytes and macrophage. 2011 , 33, 55-63	9
359	How should impaired morning function in rheumatoid arthritis be treated?. 2011 , 125, 28-39	12
358	Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. 2011 , 70, 1631-40	48
357	Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. 2012 , 6, 429-64	42
356	Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis. 2012 , 32, 1055-7	18
355	GADD45 β regulates TNF- α and IL-6 synthesis in THP-1 cells. 2012 , 61, 1195-202	8

354	Comparison of patient satisfaction with two different etanercept delivery systems. A randomised controlled study in patients with rheumatoid arthritis. 2012 , 71, 890-9	10
353	Nonserious infections: should there be cause for serious concerns?. 2012 , 38, 707-25	9
352	Inmunoterapia con agentes biológicos e infecciones fúngicas: riesgos y beneficios. 2012 , 16, 73-81	1
351	Etanercept: efficacy and safety for approved indications. 2012 , 11, 121-39	55
350	Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment. 2012 , 11, 911-21	15
349	A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. 2012 , 51, 600-9	49
348	Biological agents for the treatment of uveitis. 2012 , 12, 311-28	25
347	Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. 2012 , 18, 1044-54	36
346	Therapeutic effects of a novel tylophorine analog, NK-007, on collagen-induced arthritis through suppressing tumor necrosis factor production and Th17 cell differentiation. 2012 , 64, 2896-906	31
345	Evolution of treatment for rheumatoid arthritis. 2012 , 51 Suppl 6, vi28-36	96
344	Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases. 2012 , 224, 72-83	3
343	Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis. 2012 , 46, 1491-505	15
342	Nitroglycerin prevents coagulopathies and foetal death associated with abnormal maternal inflammation in rats. 2012 , 107, 864-74	12
341	Emerging adverse cutaneous drug reactions. 2012 , 30, 695-730, vii	3
340	Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. 2012 , 32, 3851-6	22
339	The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis. 2012 , 12, 167	15
338	Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. 2012 , 7, e30275	189
337	Etanercept, a widely used inhibitor of tumor necrosis factor- α (TNF- α) prevents retinal ganglion cell loss in a rat model of glaucoma. 2012 , 7, e40065	141

336	Comparison Korean National Health Insurance Reimbursement and Other Guidelines for TNF- α Blocker in Rheumatoid Arthritis. 2012 , 19, 334	5
335	Small Molecule Inhibitors in Rheumatoid Arthritis. 2012 , 19, 118	3
334	Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?. 2012 , 21, 524-34	28
333	A high molecular weight protein extract of <i>Mastobranchus indicus</i> (Mi-64) having antiarthritic activity in experimental animals. 2012 , 35, 1223-31	
332	Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis. 2012 , 32, 1511-9	17
331	Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. 2012 , 12, 322-9	67
330	S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. 2012 , 10 Suppl 2, S1-95	197
329	Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. 2013 , 14, 13	35
328	Rheumatoid Disease and Other Inflammatory Arthropathies. 2013 , 1-29	
327	Etanercept in the treatment of rheumatoid arthritis. 2013 , 13, 1441-50	5
326	Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. 2013 , 22, 3192-202	155
325	Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNF α therapy and discontinuation of glucocorticoids. 2013 , 33, 2001-7	9
324	Inhibition of In Vitro TNF- α Production by <i>Anisomeles malabarica</i> R.Br. Reinforces Its Anti-Rheumatic and Immunomodulatory Properties. 2013 , 83, 187-191	
323	Etanercept. 2013 , 255-282	1
322	Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis. 2013 , 52, 2127-35	22
321	The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. 2013 , 72, 1947-55	270
320	A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis. 2013 , 32, 99-108	10
319	The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. 2013 , 305, G763-85	69

318	Review of the Biological Agents Used for Immune-Mediated Inner Ear Disease. 2013 , 64, 223-229	2
317	Review of the biologic agents used for immune-mediated inner ear disease. 2013 , 64, 223-9	8
316	Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. 2013 , 9, 164-72	292
315	Creative trial design in RA: optimizing patient outcomes. 2013 , 9, 183-94	12
314	Update on biologics for treatment of juvenile idiopathic arthritis. 2013 , 13, 361-76	43
313	Etanercept for the treatment of rheumatoid arthritis. 2013 , CD004525	33
312	Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. 2013 , 72, 1927-33	21
311	Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. 2013 , 42, 813-8	46
310	Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. 2013 , 65, 1732-42	29
309	Incorporating data from various trial designs into a mixed treatment comparison model. 2013 , 32, 2935-49	58
308	Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly. <i>Modern Rheumatology</i> , 2013 , 23, 994-1000	3.3 3
307	Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. 2013 , 13, 760-73	24
306	Bone-targeting endogenous secretory receptor for advanced glycation end products rescues rheumatoid arthritis. 2013 , 19, 183-94	17
305	Clinical Characteristics of Korean Rheumatoid Arthritis Patients with Indications for TNF-Blocker. 2013 , 20, 356	4
304	Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. 2014 , 8, 141-53	40
303	Immune Compromise Associated with Biologics. 2014 , 889-906	2
302	Optimal dose of etanercept in the treatment of rheumatoid arthritis. 2014 , 6, 27-38	
301	Are sample sizes of randomized clinical trials in rheumatoid arthritis too large?. 2014 , 44, 1034-44	4

300	Tissue specific CD4+ T cell priming determines the requirement for interleukin-23 in experimental arthritis. 2014 , 16, 440	3
299	Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis. 2014 , 14, 893-904	8
298	Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase. 2014 , 14, 1761-7	6
297	Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. 2014 , 66, 1653-61	104
296	Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort. 2014 , 66, 173-9	25
295	Drug safety evaluation of certolizumab pegol. 2014 , 13, 255-66	15
294	Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). 2014 , 54, 109-19	23
293	Generalization and extrapolation of treatment effects from clinical studies in rheumatoid arthritis. 2014 , 66, 998-1007	4
292	Early tissue responses in psoriasis to the antitumour necrosis factor- β biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. 2014 , 171, 97-107	27
291	Efficacy and safety of etanercept in chronic immune-mediated disease. 2014 , 13, 649-61	22
290	Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. 2014 , 12, 102	39
289	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. <i>Modern Rheumatology</i> , 2014 , 24, 734-43	33 8
288	Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers. 2014 , 3, e000560	21
287	Suppression of cerebral aneurysm formation in rats by a tumor necrosis factor- β inhibitor. 2014 , 120, 1193-200	21
286	Ankylosing spondylitis in a military aviator: air medical considerations. 2014 , 33, 115-7	
285	[Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologics in Germany : real-life clinical practice data]. 2014 , 73, 65-73	2
284	Rituximab and tocilizumab for the treatment of rheumatoid arthritis. 2014 , 30, 282-8	6
283	Hierarchical network meta-analysis models to address sparsity of events and differing treatment classifications with regard to adverse outcomes. 2014 , 33, 2449-66	17

282	Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. 2014 , 73, 2094-100	38
281	Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients. 2014 , 63, 409-14	26
280	The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. 2014 , 127, 1208-32	78
279	Anti-inflammatory potential of alpha-linolenic acid mediated through selective COX inhibition: computational and experimental data. 2014 , 37, 1297-306	33
278	Fishing for fire: strategies for biological targeting and criteria for material design in anti-inflammatory therapies. 2014 , 25, 478-498	22
277	B cells participate in tolerance and autoimmunity through cytokine production. 2014 , 47, 1-12	40
276	Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. 2014 , 36, 737-47	36
275	Biologics registers in rheumatoid arthritis. 2014 , 42, 262-265	
274	Steroid-sparing effects of etanercept in a patient with steroid-dependent adult-onset Still's disease. 2014 , 53, 1209-13	9
273	Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. 2015 , 55 Suppl 3, S60-74	31
272	Early changes in fatigue and cytokine concentration following etanercept treatment in rheumatoid arthritis. 2015 , 10, 79-84	
271	Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. 2015 , 172, 169-74	23
270	Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. 2015 , 11, 1325-35	8
269	Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. 2015 , 10, e0137258	13
268	Rheumatoid Arthritis - Anti-TNF. 2015 , 27, 180-4	25
267	Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis. 2015 , 15, 883-93	15
266	TNFR1 and TNFR2 Expression and Induction on Human Treg Cells from Type 1 Diabetic Subjects. 2015 , 4, 34-47	4
265	Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. 2015 , 67, 280-309	224

264	Emerging targets in treating pain. 2015 , 28, 379-97	13
263	Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. 2015 , 74, 1825-9	41
262	An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies. 2015 , 21, 115-9	18
261	Treatment of rheumatoid arthritis: Unraveling the conundrum. 2015 , 65, 1-18	73
260	Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain. 2015 , 13, 11	4
259	Inflammation induced loss of skeletal muscle. 2015 , 80, 131-142	121
258	Etanercept biosimilars. 2015 , 35, 197-209	43
257	An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. 2016 , 22, 1088-102	23
256	Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis. 2016 , 31, 634-42	33
255	Mixed Treatment Comparison and Bayesian Integrated Economic Evaluation of Cost-Effectiveness and Budget Impact of TNF-alpha inhibitors for Rheumatoid Arthritis after Failure of Conventional DMARD Therapy. 2016 , 34, 145	
254	Ellagic acid alleviates adjuvant induced arthritis by modulation of pro- and anti-inflammatory cytokines. 2016 , 41, 339-349	23
253	Novel Human Three-Domain Antibody Fragments Against sTNF α s Well as tmTNF α with High Affinity Generated by the Combination of Ribosome Display and E. coli Expression System. 2016 , 83, 267-78	4
252	Neuropharmacologic Approaches to Restore the Brain's Microenvironment. 2016 , 11, 484-94	9
251	Biologic interventions for fatigue in rheumatoid arthritis. 2016 , CD008334	37
250	Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials. 2016 , 2, e000323	11
249	A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor β ameliorates experimental arthritis. 2016 , 6, 20150	22
248	New therapeutic approaches in rheumatoid arthritis. 2016 , 45, e179-92	4
247	Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. 2016 , 388, 239-47	76

246	Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance. 2016 , 33, 387-98		16
245	Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis. 2016 , 56, 835-44		13
244	A randomized phase I pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects. 2016 , 82, 64-73		43
243	Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). 2016 , 11, CD012437		18
242	Effects of the stem extracts of Schisandra glaucescens Diels on collagen-induced arthritis in Balb/c mice. 2016 , 194, 1078-1086		8
241	The Burden of Rheumatic Diseases: An Analysis of an Italian Administrative Database. 2016 , 3, 167-177		5
240	Co-culture of fibroblast-like synoviocytes with umbilical cord-mesenchymal stem cells inhibits expression of pro-inflammatory proteins, induces apoptosis and promotes chondrogenesis. <i>Molecular Medicine Reports</i> , 2016 , 14, 3887-93	2.9	5
239	Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. 2016 , 68, 1478-88		37
238	Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. 2016 , CD012183		36
237	Efficacy of etanercept for treating the active rheumatoid arthritis: an updated meta-analysis. 2016 , 19, 1132-1142		5
236	DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing. 2016 , 17, 202		16
235	Treatment of psoriasis. 2016 , 43-84		
234	Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials. 2016 , 68, 299-307		6
233	Cytokine inhibitors. 2016 , 39-69		
232	Clinical Characteristics and Cytokine Profiles of Organizing Pneumonia in Patients with Rheumatoid Arthritis Treated with or without Biologics. <i>Journal of Rheumatology</i> , 2016 , 43, 738-44	4.1	6
231	Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study. <i>Journal of Rheumatology</i> , 2016 , 43, 495-503	4.1	28
230	Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. 2016 , 24, 776-85		19
229	Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease. 2016 , 10, 69-76		19

228 Biologic Therapies. **2016**, 160-166.e4

227	Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. 2016 , 75, 52-8	88
226	A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. 2017 , 76, 51-57	157
225	A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. 2017 , 76, 65-71	32
224	Effect of tumor necrosis factor- α inhibitors on ambulatory 24-h blood pressure. 2017 , 26, 24-29	6
223	Rapid subcutaneous desensitization for treatment of hypersensitivity reactions to etanercept in two patients with positive basophil activation test. 2017 , 66, 357-359	10
222	Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. 2017 , 56, 725-735	13
221	CaMKII α subtypes differentially regulate infarct formation following ex vivo myocardial ischemia/reperfusion through NF- κ B and TNF- α 2017 , 103, 48-55	40
220	The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar. 2017 , 33, 993-1003	19
219	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. 2017 , 3, CD012591	29
218	Regulatory B cells in rheumatoid arthritis: Alterations in patients receiving anti-TNF therapy. 2017 , 184, 63-69	19
217	Anti-drug antibodies in Colombian patients with rheumatoid arthritis treated with Enbrel vs Etanar - Preliminary report. 2017 , 14, 103-108	1
216	Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective. 2017 , 37, 1423-1434	18
215	A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. 2017 , 76, 831-839	91
214	Tratamiento de la artritis reumatoide. 2017 , 12, 1626-1638	2
213	Anti-Toxoplasma antibodies in Egyptian rheumatoid arthritis patients. 2017 , 37, 785-790	3
212	Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study. 2017 , 33, 657-666	10
211	Évaluation de l'activité de la polyarthrite rhumatoïde. 2017 , 84, 343-346	

210	Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. 2017 , 21, 2S-40S	5
209	Treatment with Biologicals in Rheumatoid Arthritis: An Overview. 2017 , 4, 247-261	86
208	Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis. 2017 , 34, 2093-2103	9
207	2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. 2017 , 20, 1166-1184	7
206	Prediction of Response to Targeted Treatment in Rheumatoid Arthritis. 2017 , 92, 1129-1143	50
205	Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. 2017 , 46, 584-593	23
204	Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study. 2017 , 37, 943-947	1
203	Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. 2017 , 8, 460	162
202	Anti-cytokine Therapies. 2017 , 999-1019	1
201	Matrix Metalloproteinase Gene Activation Resulting from Disordered Epigenetic Mechanisms in Rheumatoid Arthritis. 2017 , 18,	45
200	Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. 2017 , 2017, 8417249	25
199	Delayed anti-TNF therapy increases the risk of total knee replacement in patients with severe rheumatoid arthritis. 2017 , 18, 326	2
198	Age-related trends in injection site reaction incidence induced by the tumor necrosis factor- α (TNF- α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. 2017 , 14, 102-109	16
197	Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. 2018 , 57, 354-369	19
196	Tumor Necrosis Factor Inhibition. 2018 , 111-121	
195	Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. 2018 , 6, 15	501
194	Evolution of clinical trials for rheumatoid arthritis and spondyloarthritis. 2018 , 30, 340-346	1
193	Etanercept for the treatment of rheumatoid arthritis. 2018 , 10, 433-445	36

192	Expression levels of selected genes can predict individual rheumatoid arthritis patient response to tumor necrosis factor alpha blocker treatment. 2018 , 34, 1777-1783	
191	The role of lymphotoxin- β in rheumatoid arthritis. 2018 , 67, 495-501	12
190	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. 2018 , 37, 315-321	27
189	A Pilot Dose-Finding Study of Etanercept in Rheumatoid Arthritis. 2018 , 11, 38-45	2
188	Anti-Inflammatory Strategies in Intrahepatic Islet Transplantation: A Comparative Study in Preclinical Models. 2018 , 102, 240-248	22
187	Assessing joint destruction in the knees of patients with rheumatoid arthritis by using a semi-automated software for magnetic resonance imaging: therapeutic effect of methotrexate plus etanercept compared with methotrexate monotherapy. <i>Modern Rheumatology</i> , 2018 , 28, 235-241	3.3
186	Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment. 2018 , 56, 340-345	4
185	Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials. 2018 , 2, rky045	1
184	Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis. 2018 , 20, 84	17
183	Anti TNF- α therapy in patients with relapsed and refractory Langerhans cell histiocytosis: a phase II study. 2018 , 35, 362-368	2
182	20 years of experience with tumour necrosis factor inhibitors: what have we learned?. 2018 , 57, vii5-vii10	24
181	Pharmacoeconomic evaluation of treatment effectiveness with selected biologic treatment in rheumatoid arthritis therapy. 2018 , 56, 212-218	
180	Risk of infection associated with anti-TNF- α therapy. 2018 , 16, 939-956	33
179	NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. 2018 , 194, 231-243	106
178	Immunotherapeutic Approaches of Rheumatoid Arthritis and the Implication on Novel Interventions for Refractoriness. 2018 ,	
177	Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis. 2018 , 89, 1-6	15
176	Breaking the Barrier - Potent Anti-Inflammatory Activity following Efficient Topical Delivery of Etanercept using Thermoresponsive Nanogels. 2018 , 8, 450-463	45
175	Future Research Strategies and Directions in Recurrent Pregnancy Loss. 2018 , 283-292	

174	Distinguishing rheumatoid arthritis from psoriatic arthritis. 2018 , 4, e000656	50
173	Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. 2018 , 35, 1535-1563	40
172	The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. 2018 , 11, 1558-1570	46
171	Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. 2018 , 17, 727-732	57
170	Efficacy and safety of biological agents in the older rheumatoid arthritis patients compared to Young: A systematic review and meta-analysis. 2019 , 48, 799-807	13
169	Increased Nonexudative Age-Related Macular Degeneration Diagnosis Among Medicare Beneficiaries With Rheumatoid Arthritis. 2019 , 60, 3520-3526	4
168	Bedside to bench: defining the immunopathogenesis of psoriatic arthritis. 2019 , 15, 645-656	20
167	TNF- α antagonist attenuates systemic lipopolysaccharide-induced brain white matter injury in neonatal rats. 2019 , 20, 45	6
166	Deletion at 2q14.3 is associated with worse response to TNF- β blockers in patients with rheumatoid arthritis. 2019 , 21, 195	1
165	Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts. 2019 , 8,	18
164	Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis. 2019 , 15, 33-54	11
163	[Etanercept in routine German clinical practice to treat rheumatoid arthritis patients : A one-year observational study on effectiveness, safety and health economics]. 2019 , 78, 552-558	1
162	Sources of Pathogenic Nucleic Acids in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2019 , 10, 1028	8.4 25
161	Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38 β MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF- β inhibitory properties. <i>Bioorganic Chemistry</i> , 2019 , 87, 550-559	5.1 18
160	Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. 2019 , 101, 1003-1015	18
159	Effects of bovine tumor necrosis factor alpha decoy receptors on cell death and inflammatory cytokine kinetics: potential for bovine inflammation therapy. 2019 , 15, 68	3
158	Natural chromones as potential anti-inflammatory agents: Pharmacological properties and related mechanisms. 2019 , 72, 31-39	17
157	Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients. 2019 , 44, 384-396	5

156	Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis. 2019 , 35, 36-44	4
155	Critical parameters for the controlled synthesis of nanogels suitable for temperature-triggered protein delivery. 2019 , 100, 141-151	17
154	Conferring extracellular matrix affinity enhances local therapeutic efficacy of anti-TNF- α antibody in a murine model of rheumatoid arthritis. 2019 , 21, 298	5
153	Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again. 2019 , 8, e011343	31
152	Injection site reactions with the use of biological agents. 2019 , 32, e12817	18
151	The importance of inhibition of a catabolic pathway of methotrexate metabolism in its efficacy for rheumatoid arthritis. 2019 , 122, 10-15	1
150	Strategies toward rheumatoid arthritis therapy; the old and the new. 2019 , 234, 10018-10031	134
149	Cytokine targeting in rheumatoid arthritis. 2019 , 206, 3-8	11
148	Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry. 2020 , 2, 588-594	3
147	Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients. 2020 , 3, 91-104	11
146	Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. 2020 , 37, 3732-3745	3
145	New Rheumatoid Arthritis Treatments for 'Old' Patients: Results of a Systematic Review. 2020 , 37, 3676-3691	1
144	Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis. 2020 , 7, 775-792	7
143	Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis. 2020 , 50, 822-826	2
142	The Role of Chronic Inflammatory Bone and Joint Disorders in the Pathogenesis and Progression of Alzheimer's Disease. 2020 , 12, 583884	5
141	Multi-HLA class II tetramer analyses of citrulline-reactive T cells and early treatment response in rheumatoid arthritis. 2020 , 21, 27	11
140	Death Receptors and Their Ligands in Inflammatory Disease and Cancer. 2020 , 12,	10
139	TNF-Related Apoptosis-Inducing Ligand Receptor 1 in Patients With Ankylosing Spondylitis. 2020 , 26, 242-247	1

138	Rheumatoid arthritis in the elderly: Characteristics and treatment considerations. 2020 , 19, 102528		16
137	Therapeutic potential of TNF- α inhibitors in chronic inflammatory disorders: Past and future. 2021 , 8, 38-47		7
136	Tumor Necrosis Factor Inhibitors. 2021 , 287-301.e7		2
135	Challenges for biosimilars: focus on rheumatoid arthritis. 2021 , 41, 121-153		4
134	Clinical trials of promising apoptosis modulating drugs. 2021 , 329-391		1
133	Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corona registry data. 2021 , 41, 381-390		4
132	Radiographic and clinical effects of 10 mg and 25 mg twice-weekly etanercept over 52 weeks in Japanese patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2021 , 31, 319-325	3-3	0
131	Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus. 2021 , 117, 2309-2325		10
130	Long-term remission and biologic persistence rates: 12-year real-world data. 2021 , 23, 25		14
129	The Role of Tumor Necrosis Factor Alpha (TNF- α) in Autoimmune Disease and Current TNF- α Inhibitors in Therapeutics. 2021 , 22,		61
128	Effectiveness, safety and economic analysis of Benepali in clinical practice. 2021 , 17, 588-594		0
127	A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor- α Inhibitors: The NETWORK-004 Prospective Observational Study. 2021 , 8, 1159-1176		6
126	Efectividad y seguridad en el manejo de enfermedades inflamatorias crónicas con medicamentos biosimilares de etanercept e infliximab en pacientes colombianos. 2021 ,		
125	Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension. 2021 , 13, 817-857		3
124	Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study. 2021 , 38, 1290-1300		1
123	Chemokine and Cytokine Modulators. 2003 , 119-192		1
122	Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. 5, 119-133		75
121	Control of osteoclast activity and bone loss by IKK subunits: new targets for therapy. 2007 , 602, 125-34		14

120	Anti-inflammatory effects of a novel TNFR1-selective antagonistic TNF mutant on established murine collagen-induced arthritis. 2011 , 691, 493-500		5
119	Regulation of cytokine production by inhibitors of cell signalling. 2000 , 43-82		1
118	Pharmacokinetics, efficacy, and safety of short-term (12 weeks) etanercept for methotrexate-refractory polyarticular juvenile idiopathic arthritis in Japan. <i>Modern Rheumatology</i> , 2005 , 15, 397-404	3.3	6
117	T-cell activation via CD26 and caveolin-1 in rheumatoid synovium. <i>Modern Rheumatology</i> , 2006 , 16, 3-13	3.3	29
116	Guidelines for the proper use of etanercept in Japan. <i>Modern Rheumatology</i> , 2006 , 16, 63-7	3.3	24
115	Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. <i>Modern Rheumatology</i> , 2006 , 16, 77-84	3.3	22
114	Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. <i>Modern Rheumatology</i> , 2009 , 19, 488-92	3.3	12
113	Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan. <i>Modern Rheumatology</i> , 2010 , 20, 107-13	3.3	3
112	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2011 , 21, 343-51	3.3	36
111	Rheumatic Diseases. 2006 , 1383-1408		2
110	Management of Psoriatic Arthritis. 2007 , 97-113		1
109	Treatment of Rheumatoid Arthritis: Tumor Necrosis Factor Inhibitors. 2009 , 337-349		2
108	Treatment of Rheumatoid Arthritis. 2009 , 1119-1143		4
107	Anticytokine Therapies. 2013 , 957-977.e4		1
106	Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. 2002 , 73, 665-7		89
105	Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome. 2008 , 29, 560-71		4
104	Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. 2009 , 102, 1133-40		32
103	Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. 2001 , 107, 1519-27		107

102	Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. 2003 , 111, 915-24	90
101	The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. 2004 , 114, 471-4	67
100	The Structure of Human Interferon-b-1a (Avonex1fi) and its Relation to Activity. 2003 , 483-519	4
99	A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients. 2016 , 11, e0152362	15
98	[Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]. 2011 , 152, 919-28	2
97	Etanercept - review of efficacy and safety after five years of clinical use. 2004 , 1, 11-23	1
96	A new generation of high-affinity humanized PEGylated Fab? fragment anti-tumor necrosis factor? monoclonal antibodies. 2006 , 3, 535-545	4
95	Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. 2009 , 3, 485-98	17
94	Adalimumab in the treatment of arthritis. 2007 , 3, 133-48	40
93	Safety and efficacy of etanercept in the elderly. 2006 , 2, 189-197	2
92	Tacrolimus for the treatment of rheumatoid arthritis: are broad-based immunosuppressants still valid?. 2006 , 1, 661-672	1
91	Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis. 2015 , 29, 124-39; discussion 139-40	59
90	Solution of a mathematical model for the treatment of rheumatoid arthritis. 2019 , 10, 12-24	1
89	Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. 2016 , 28, 1-616	58
88	A case of tuberculous arthritis following the use of etanercept. 2009 , 24, 397-401	4
87	Biologic Agents in Rheumatic Diseases. 2012 , 82, 549	3
86	Antibodies to Tumor Necrosis Factors in the Treatment of Rheumatoid Arthritis and Spondyloarthritis: The Basic Science, Clinical Science and Unmet Needs; Results from a Single Center. 2014 , 04, 86-92	2
85	A Single Center Experience in Biological Therapy for the Treatment of Rheumatoid Arthritis in Saudi Arabia. 2014 , 04, 199-206	1

- 84 Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: preliminary results. **2014**, 25, 168-75 18
- 83 Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF- α antagonist therapy: a meta-analysis of randomized control trials. **2014**, 15, 3403-10 19
- 82 The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports. **2019**, 8, 212554 1
- 81 The Role of Neurohormonal Systems, Inflammatory Mediators and Oxydative Stress in Cardiomyopathy. 0
- 80 Rheumatoid Arthritis. **2000**, 100, 40-43
- 79 Tumor necrosis factor (TNF) inhibition in the treatment of vasculitis. **2001**, 41-63
- 78 Osteoporosis Associated with Rheumatologic Disorders. **2001**, 351-362 1
- 77 Neue Arzneimittel. **2001**, 23-71
- 76 CURRENT CONCEPTS REGARDING PHARMACOLOGIC TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS. **2001**, 17, 321-338 2
- 75 Immune System Modulators. **2001**,
- 74 Antibody Engineering.
- 73 Neue Basistherapeutika unter dem Blickwinkel einer evidenzbasierten Therapie. **2002**, 32-35
- 72 Basistherapie der rheumatoiden Arthritis. **2002**, 24,
- 71 Tumor Necrosis Factor _ and Interleukin-1_ Inhibitory Therapies. **2002**, 225-245
- 70 Rheumatoide Arthritis. **2003**, 255-289
- 69 Conception actuelle du traitement de la polyarthrite rhumatoïde : vers une révolution thérapeutique ?. **2003**, 187, 957-976
- 68 The role of tumour necrosis factor in rheumatoid arthritis. **2004**, 1-28
- 67 Is IL-6 a therapeutic target?. **2004**, 89-106

- 66 Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia. **2004**, 269-298
- 65 The clinical use of anti-cytokine therapy in rheumatic diseases. **2004**, 107-125
- 64 Safety issues with anti-TNF agents. **2004**, 133-161
- 63 Etanercept. **2004**, 47-69
- 62 Targeting DMARD therapy. **2005**, 25-47
- 61 TNF-Inhibitors. **2005**, 265-278
- 60 Impact of TNF inhibitors on rheumatoid arthritis. **2006**, 26, 148-159 2
- 59 Osteoporosis Associated with Rheumatologic Disorders. **2008**, 1387-1398 1
- 58 Anticytokine Therapies. **2009**, 929-946
- 57 Perspectives in targeted therapy. **2009**, 207-220
- 56 Biologic Therapies For Inflammatory Bowel Disease. **2009**,
- 55 Biologic Therapies In Rheumatoid Arthritis. **2009**,
- 54 Growth Factors and Cytokines.
- 53 Arthritic Disorders. **2011**, 632-650
- 52 Osteoporosis. **2011**, 701-706
- 51 Nonsteroidal Anti-inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, and Agents Used in Gout. **2012**, 415-475 1
- 50 Protein Delivery System based on Various Polysaccharides. **2011**, 41, 197-204
- 49 Study of the Efficacy in RA Patients Switching from Etanercept 25 mg Twice a Week to 50 mg Once a Week. **2012**, 38, 723-728

- 48 Rheumatology and Musculoskeletal Problems. **2012**, 648-689
- 47 Biologic Therapies. **2013**, 357-383
- 46 Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population. **2014**, 2, e385
- 45 New Frontiers in RPL Research and Treatment. **2016**, 185-202
- 44 An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. **2016**, 22, 1092-1106
- 43 Traitements biologiques des rhumatismes inflammatoires chroniques : résultats cliniques. **2018**, 202, 1927-1937
- 42 Treating Rheumatoid Arthritis Through the Life Course. **2020**, 185-200
- 41 Analytical and clinical validation of an RNA sequencing-based assay for quantitative, accurate evaluation of a molecular signature response classifier in rheumatoid arthritis. **2021**, 21, 1235-1243 1
- 40 Therapie mit Biologika. **2005**, 443-458
- 39 Rheumatische Erkrankungen. **2004**, 367-388
- 38 Etanercept in rheumatology. **2006**, 45-54
- 37 Biologic Therapies. **2008**, 403-427
- 36 Development of Biological Therapies for Inflammatory Arthritis. **2008**, 37-49
- 35 Blocking the effect of interleukin-1 and tumor necrosis factor in rheumatoid arthritis is well tolerated and effective. **2004**, 1, 255-266
- 34 Rheumatische Erkrankungen. **2007**, 355-370
- 33 Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab. *Modern Rheumatology*, **2010**, 20, 561-5 3:3 3
- 32 Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly. *Modern Rheumatology*, **2013**, 23, 994-1000 3:3
- 31 Efectividad, seguridad y análisis económico de Benepali en práctica clínica. **2021**, 17, 588-594

30	Cytokine blockers in psoriatic arthritis. 2001 , 60 Suppl 3, iii37-40		2
29	Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). 2001 , 60 Suppl 3, iii2-5		7
28	TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. 2009 , 15, 1418-28		166
27	Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. 2009 , 3, 443-57		21
26	A Human Monoclonal Antibody Against Tumor Necrosis Factor-alpha. 2009 , 34, 2-30		
25	Safety of etanercept in elderly subjects with rheumatoid arthritis. 2010 , 4, 1-4		9
24	Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study. 2010 , 3, 266-73		3
23	Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial. 2017 , 3, e000502		3
22	Precision drug repurposing via convergent eQTL-based molecules and pathway targeting independent disease-associated polymorphisms. 2019 , 24, 308-319		3
21	Biological macromolecules as immunomodulators. 2022 , 273-287		
20	Physician and Patient Reported Effectiveness are similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data from a Rheumatoid Arthritis Registry.. <i>Journal of Rheumatology</i> , 2022 ,	4.1	
19	Demyelinating events following anti-tumor necrosis factor alpha therapy: Rare but challenging to treat.. <i>European Journal of Neurology</i> , 2022 ,	6	0
18	Piceatannol suppresses inflammation and promotes apoptosis in rheumatoid arthritis-fibroblast-like synoviocytes by inhibiting the NF- κ B and MAPK signaling pathways.. <i>Molecular Medicine Reports</i> , 2022 , 25,	2.9	0
17	Design, synthesis, anti-inflammatory evaluation and molecular docking of novel thiophen-2-ylmethylene-based derivatives as potential TNF- α production inhibitors.. <i>Bioorganic Chemistry</i> , 2022 , 122, 105726	5.1	2
16	Toward Overcoming Treatment Failure in Rheumatoid Arthritis.. <i>Frontiers in Immunology</i> , 2021 , 12, 755884	4.4	1
15	Rheumatoid arthritis: current therapeutics compendium.. <i>Endocrine Regulations</i> , 2022 , 56, 148-162	1.9	
14	Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.. <i>Expert Review of Clinical Immunology</i> , 2022 , 1-9	5.1	0
13	Tumor necrosis factor (TNF) inhibitors. 2013 , 307-318.e4		0

12	Synthesis, anti-inflammatory properties, molecular modelling and potential COX-2, TNF- α and IL1 β inhibitors of pyrazole-based scaffolds. <i>Journal of Molecular Structure</i> , 2022 , 1266, 133499	3.4	1
11	Safety and Effectiveness of Certolizumab Pegol in Japanese Patients with Rheumatoid Arthritis: Results from a 24-Week Post-Marketing Surveillance Study. <i>Modern Rheumatology</i> ,	3.3	0
10	Rheumatology: Problem, Promise and Pitfalls. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2000 , 30, 191-198	0.9	
9	Reasons and Risk Factors For Discontinuation of Treatment with Any Biological Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Long-term Observational Study.		
8	Heritable and Polygenic Inflammatory Disorders. 2023 , 321-356		0
7	Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis. 2022 , 60, 427-437		2
6	A Review of the Safety of Interleukin-17A Inhibitor Secukinumab. 2022 , 15, 1365		0
5	The Role of Bone Morphogenetic Protein Receptor Type 2 (BMP2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling. 2022 , 11, 3823		0
4	The Evolution of TNF- α Blockade for the Treatment of Rheumatoid Arthritis. 2022 , 16,		0
3	Effectiveness and safety in the management of chronic inflammatory diseases with etanercept and infliximab biosimilars in Colombian patients. 2023 ,		0
2	Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. 2023 , 12, 1630		1
1	Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor.		0